There's a study called SURMOUNT-MAINTAIN on this. Its takeaway was to stay on tirzepatide on the smallest dose that you can handle instead of quitting outright. Some people went from the 10-15 mg range down to 5 mg, and kept most of the loss, while those who stopped regained a lot more on average. Habits still count, but it points toward treating obesity like a long-term condition that can need ongoing medication.